Status
Conditions
Treatments
About
Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.
Full description
Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Loading...
Central trial contact
Hui Lin Yeh, M.D.; Weir Chiang You, M.D. Ph.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal